Abciximab has been studied in three phase 3 clinical trials: EPIC, EPILOG, and CAPTURE.
Here is how abciximab is currently being used. It is a prescription-only medication and is only indicated for intravenous (IV) use. Further studies and randomized controlled trials (RCTs) need to be conducted to provide more interventions for this drug. Studies have shown abciximab to be effective in the prevention of ischemic cardiac complications in patients undergoing percutaneous coronary intervention and prevention of ischemic cardiac complications in patients with unstable angina (UA)/non-ST-elevation myocardial infarction (NSTMI) unresponsive to conventional therapy when PCI is scheduled within 24 hours. Abciximab has only been studied in use with aspirin and heparin.
Abciximab is the Fab antibody fragment of chimeric human-murine monoclonal antibody 7E3. Inhibits platelet aggregation by reversibly binding to platelet IIb/IIIa receptors, which in turn results in steric hindrance. It prevents the binding of fibrinogen, von Willebrand factor, and other adhesive molecules during clot formation. A second action which has not been studied is the impact of Abciximab binding onto the Mac-1 integrin receptor on activated monocytes. Inhibition is produced in a dose-dependent fashion. This produces an environment similar to the autosomal recessive disease Glanzmann thrombasthenia, which is marked by an inherent decrease in GPIIB-IIa receptors on the surface of the platelet. Laboratory findings in this condition include an increased bleeding time with no change in platelet count, PT or PTT. Do not confuse this with the pathogenesis of Von Willebrand disease or Bernard-Soulier syndrome. These are diseases of platelet adhesion, in contrast to Glanzmann thrombasthenia, which is a disorder of platelet aggregation. Clopidogrel and ticagrelor are drugs that decrease platelet adhesion and are useful in preventing ischemic stroke. Platelet adhesion is a commonly mistaken mechanism for abciximab. Abciximab produces its effect over a short half-life of approximately 30 minutes, allowing it to be used as a short-term platelet aggregation inhibitor on the way to the cath lab for PCI. Its effects on platelets last for 48 hours after administration and can still be seen in low potency up to 15 days after administration.
Typically supplied as Reopro IV solution of 2 mg/1 ml.
Percutaneous coronary intervention (PCI): 0.25 mg/kg IV bolus administered 10 to 60 minutes before the start of PCI followed by infusion of 0.125 mcg/kg/min for 12 hours, not to exceed 10 mcg per minute.
Unstable angina/non-ST-elevation MI (UA/NSTEMI) unresponsive to conventional medical therapy with planned PCI within 24 hours: 0.25 mg/kg IV bolus followed by an 18 t 24-hour infusion of 10 mcg/min, concluding one hour after PCI. An ACT of 300 seconds and an aPTT of 70 seconds should be aimed for while completing PCI. Dosage does not need to be changed for patients with renal failure.
Infuse at a maximum rate of 10 mcg per minute and do not mix with other drugs.
Aneurysm of coronary vessels: Kawasaki disease (off-label use, 2 months to 7 years) 0.25 mg/kg IV loading dose by bolus, followed by an infusion of 0.125 mcg/kg/minute for 12 hours. Standard therapy includes IV gamma globulin 2 gm/kg, give 24 to 48 hours before abciximab, and aspirin 80 to 100 mg/kg per day. All subjects were heparinized and also stabilized on warfarin before hospital discharge (study dosage).
Rare but severe side effects include thrombocytopenia, anaphylaxis, major hemorrhage (cerebrovascular, pulmonary), and non-hemorrhagic cerebrovascular accident.
Abciximab administration is not associated with a higher risk of bleeding in those undergoing CABG treatment.
Pregnancy category C risk has not been ruled out. Infant risk while breastfeeding has not been studied.
All of the followings are contraindications for the use of abciximab:
Monitor complete blood counts (CBCs), prothrombin time (PT), activated clotting time, and signs and symptoms of bleeding.
There is not a minimum toxic dose listed. It is advised to begin with the therapeutic dose and to monitor patient response carefully. There is not enough research to verify the efficacy or safety of abciximab use in pediatric patients.
Approximately 5% of those treated with abciximab will develop bleeding, but due to inpatient administration, overdose is highly unlikely. In several case reports, gastrointestinal bleeding and thrombocytopenia have been described as adverse effects. Bleeding at infusion sites is the most common adverse effect and would likely worsen at toxic levels. Infusion with COX inhibitors or other anti-platelet drugs increases the risk for toxicity and adverse effects.
In the event of toxicity or adverse effects, transfuse the patient with platelets with severe thrombocytopenia. If the patient becomes hypotensive, deliver a fluid bolus.
No antidote exists for reversing abciximab.
Hemodialysis may be used to remove toxic levels of the drug successfully.
Toxic/adverse effects of abciximab are quality for admission criteria due to the need for continuous monitoring of hematologic stability.
Important questions and considerations to ask about or explain to the patient before use include:
Abciximab is widely used in interventional cardiology for the treatment of unstable angina and as an adjunct therapy following percutaneous coronary intervention. The drug is only used intravenously. Healthcare workers including nurses, pharmacists, and clinicians should be aware that one of the most common complications of abciximab is bleeding and work together as a team to identify this complication early. Patients who receive this agent must be monitored for bleeding at the IV access site and the groin. Because there is no specific antidote to reverse bleeding, it is vital to avoid other anticoagulants at the same time. In addition, the platelet count must be followed since abciximab can cause thrombocytopenia. If bleeding occurs, a consult with the hematologist is highly recommended.